Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies. LeBlanc TW. Leuk Lymphoma 2023;64:910-912.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

LeBlanc TW. Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies. Leuk Lymphoma 2023;64:910-912.
PMID: 37166176